PGT-M & PGT-A
Preimplantation Genetic Testing-Monogenic (PGT-M) and Preimplantation Genetic Testing for Aneuploidies (PGT-A) allows screening of embryos prior to implantation for genetic and chromosomal abnormalities to select the best possible embryo for transfer.
Preimplantation Genetic Testing-Monogenic (PGT-M)
Preimplantation Genetic Testing-Monogenic (PGT-M single gene) is particularly beneficial to couples who may be at risk of passing on a known genetic condition to their children such as:
- Huntington’s disease
- Cystic Fibrosis
- Sickle Cell Anaemia
- Tay-Sachs disease
- Haemophilia A
- Achondroplasia (dwarfism)
- Muscular Dystrophy
Patients considering PGT-M generally carry genes associated with a serious genetic disorder and seek PGT-M with the aim of having a child free of disease.
The process involves removing a few cells from embryo(s) at the Day 5 or Day 6 stage of development after fertilisation (embryo biopsy) and evaluating whether they carry any causative genes. The embryos are frozen after the biopsy, while the genetic testing is being undertaken.
If the genetic testing confirms patients have embryos unaffected for the genetic condition being screened for, one is selected for implantation and the remaining embryos are stored for potential future use.
PGT-M will allow Alison to determine the genetic health of your embryo and increase your chances of a healthy pregnancy.
Preimplantation Genetic Testing-Structural Rearrangements (PGT-SR) is used to check for structural chromosomal abnormalities, such as translocations.
Preimplantation Genetic Testing for Aneuploidy (PGT-A)
Preimplantation Genetic Testing for Aneuploidy (PGT-A) applies the technology from PGT-M to improve the chance of a successful pregnancy. PGT-A is often used by couples who are older, have experienced recurrent miscarriage or have had a number of failed embryo transfers. This method screens embryos for aneuploidy (missing or additional numbers of chromosomes), which is a leading cause of miscarriage and implantation failure.
Numerous embryos created naturally or via IVF have chromosomal abnormalities which means they will not become either an ongoing viable pregnancy or baby. PGT-A provides a way of reducing the risk of these embryos implanting only to miscarry in early pregnancy, a situation that costs patients emotionally and financially.
PGT-A identifies chromosomally abnormal embryos and will allow Alison to transfer only the chromosomally normal embryos, therefore assisting in more positive IVF outcomes.
